Literature DB >> 9097868

High-dose naltrexone and liver function safety.

M A Marrazzi1, J M Wroblewski, J Kinzie, E D Luby.   

Abstract

Studies have found naltrexone useful in the treatment of diseases other than opiate addiction in which endogenous opioids presumably play a role, such as alcoholism and eating disorders. Some of these studies involve high doses (100-200 mg bid). Because investigational studies with high doses (300 mg/day) reported clinically significant increases in liver enzyme levels, the authors measured a spectrum of liver function parameters in response to high doses of naltrexone in a double-blind, crossover trial (100 mg bid) followed by an open-label period (200 mg bid). They observed no adverse clinical or laboratory changes in liver function in association with high-dose naltrexone therapy in eating disorders.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9097868     DOI: 10.3109/10550499708993159

Source DB:  PubMed          Journal:  Am J Addict        ISSN: 1055-0496


  10 in total

1.  Depot naltrexone: long-lasting antagonism of the effects of heroin in humans.

Authors:  Sandra D Comer; Eric D Collins; Herbert D Kleber; Elie S Nuwayser; James H Kerrigan; Marian W Fischman
Journal:  Psychopharmacology (Berl)       Date:  2001-11-01       Impact factor: 4.530

2.  Hepatic safety and antiretroviral effectiveness in HIV-infected patients receiving naltrexone.

Authors:  Jeanette M Tetrault; Janet P Tate; Kathleen A McGinnis; Joseph L Goulet; Lynn E Sullivan; Kendall Bryant; Amy C Justice; David A Fiellin
Journal:  Alcohol Clin Exp Res       Date:  2011-07-28       Impact factor: 3.455

Review 3.  Opiate antagonists in children and adolescents.

Authors:  N Chabane; M Leboyer; M C Mouren-Simeoni
Journal:  Eur Child Adolesc Psychiatry       Date:  2000       Impact factor: 4.785

4.  Opioidergic consequences of dietary-induced binge eating.

Authors:  Nicholas T Bello; Zachary W Patinkin; Timothy H Moran
Journal:  Physiol Behav       Date:  2011-04-28

5.  Demographic and Clinical Characteristics of 907 Cases with Naltrexone Intoxication; a 14-Year Cross-Sectional Study.

Authors:  Mitra Rahimi; Alireza Kargar; Delara Hazegh Fetratjoo; Sayed Masoud Hosseini; Arezou Mahdavinejad; Shahin Shadnia
Journal:  Arch Acad Emerg Med       Date:  2022-05-01

Review 6.  Opioid dependence treatment: options in pharmacotherapy.

Authors:  Angela L Stotts; Carrie L Dodrill; Thomas R Kosten
Journal:  Expert Opin Pharmacother       Date:  2009-08       Impact factor: 3.889

Review 7.  Treatment of heroin (diamorphine) addiction: current approaches and future prospects.

Authors:  Gerardo Gonzalez; Alison Oliveto; Thomas R Kosten
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 8.  Cholestasis and endogenous opioids: liver disease and exogenous opioid pharmacokinetics.

Authors:  Mellar Davis
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

9.  Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial.

Authors:  Sandra D Comer; Maria A Sullivan; Elmer Yu; Jami L Rothenberg; Herbert D Kleber; Kyle Kampman; Charles Dackis; Charles P O'Brien
Journal:  Arch Gen Psychiatry       Date:  2006-02

Review 10.  Pharmacologic treatments for opioid dependence: detoxification and maintenance options.

Authors:  Herbert D Kleber
Journal:  Dialogues Clin Neurosci       Date:  2007       Impact factor: 5.986

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.